Background: The study aims to investigate the role of hypoxia-inducible factors (HIFs) in the development, progression, and therapeutic potential of glioblastomas. Methodology: The study, following PRISMA guidelines, systematically examined hypoxia and HIFs in glioblastoma using MEDLINE (PubMed), Web of Science, and Scopus. A total of 104 relevant studies underwent data extraction. Results: Among the 104 studies, global contributions were diverse, with China leading at 23.1%. The most productive year was 2019, accounting for 11.5%. Hypoxia-inducible factor 1 alpha (HIF1α) was frequently studied, followed by hypoxia-inducible factor 2 alpha (HIF2α), osteopontin, and cavolin-1. Commonly associated factors and pathways include glucose transporter 1 (GLUT1) and glucose transporter 3 (GLUT3) receptors, vascular endothelial growth factor (VEGF), phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) pathway, and reactive oxygen species (ROS). HIF expression correlates with various glioblastoma hallmarks, including progression, survival, neovascularization, glucose metabolism, migration, and invasion. Conclusion: Overcoming challenges such as treatment resistance and the absence of biomarkers is critical for the effective integration of HIF-related therapies into the treatment of glioblastoma with the aim of optimizing patient outcomes.
背景：本研究旨在探讨缺氧诱导因子（HIFs）在胶质母细胞瘤发生发展中的作用及其治疗潜力。方法：本研究遵循PRISMA指南，通过MEDLINE（PubMed）、Web of Science和Scopus数据库系统检索了胶质母细胞瘤中缺氧及HIFs的相关研究，共纳入104篇文献进行数据提取。结果：在104项研究中，全球贡献分布广泛，中国以23.1%的占比居首。2019年为研究成果最丰硕的年份，占全部研究的11.5%。缺氧诱导因子1α（HIF1α）的研究最为常见，其次为缺氧诱导因子2α（HIF2α）、骨桥蛋白和小窝蛋白-1。常关联的因子及通路包括葡萄糖转运蛋白1（GLUT1）与葡萄糖转运蛋白3（GLUT3）受体、血管内皮生长因子（VEGF）、磷脂酰肌醇3-激酶（PI3K）-Akt-雷帕霉素机制靶标（mTOR）通路以及活性氧（ROS）。HIF表达与胶质母细胞瘤的进展、生存期、新生血管形成、葡萄糖代谢、迁移及侵袭等多种特征相关。结论：克服治疗耐药性和生物标志物缺失等挑战，对于将HIF相关疗法有效整合到胶质母细胞瘤治疗中以优化患者预后至关重要。
肿瘤(癌症)患者之家